960235-24-9Relevant academic research and scientific papers
HETEROCYCLIC GLP-1 AGONISTS
-
Page/Page column 130; 131, (2022/03/22)
This disclosure relates to GLP-1 agonists of Formula (I), including pharmaceutically acceptable salts and solvates thereof, and pharmaceutical compositions including the same.
MRGPRX2 ANTAGONISTS FOR THE TREATMENT OF INFLAMMATORY DISORDERS
-
Paragraph 00115; 00215, (2021/05/15)
The present disclosure is directed to use of MrgprX2 antagonists in the treatment of inflammatory disorders, e.g., inflammatory disorders of the skin. This invention is also directed to pharmaceutical compositions comprising a MrgprX2 antagonist and a pha
ANDROGEN RECEPTOR MODULATING COMPOUNDS
-
Page/Page column 116, (2011/05/11)
Compounds of formula (I) wherein R1 to R16, A. B and E are as defined in the claims and pharmaceutically acceptable salts and esters thereof, are disclosed. The compounds of formula (I) possess utility as tissue-selective androgen receptor modulators (SARM) and are particularly useful as medicaments in the treatment of prostate cancer and other AR dependent conditions and diseases where AR antagonism is desired.
Novel methylene-linked heterocyclic EP1 receptor antagonists
Hall, Adrian,Bit, Rino A.,Brown, Susan H.,Chowdhury, Anita,Giblin, Gerard M.P.,Hurst, David N.,Kilford, Ian R.,Lewell, Xiao,Naylor, Alan,Scoccitti, Tiziana
, p. 1592 - 1597 (2008/12/22)
We describe the SAR, in terms of heterocyclic replacements, for a series of pyrazole EP1 receptor antagonists. This study led to the identification of several aromatic heterocyclic replacements for the pyrazole in the original compound. Investi
